International Assets Investment Management LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

International Assets Investment Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 99.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 21,327 shares of the company’s stock after selling 3,433,146 shares during the period. International Assets Investment Management LLC’s holdings in Johnson & Johnson were worth $3,072,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Strategic Financial Concepts LLC lifted its position in shares of Johnson & Johnson by 9,652.2% in the 2nd quarter. Strategic Financial Concepts LLC now owns 328,454 shares of the company’s stock worth $480,000 after purchasing an additional 325,086 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Johnson & Johnson by 28.8% during the 2nd quarter. Acadian Asset Management LLC now owns 923,650 shares of the company’s stock worth $134,977,000 after acquiring an additional 206,671 shares during the period. Fiducient Advisors LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $660,000. Anchor Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Anchor Capital Advisors LLC now owns 126,947 shares of the company’s stock valued at $18,555,000 after purchasing an additional 1,924 shares during the period. Finally, Lynch & Associates IN grew its stake in Johnson & Johnson by 2.6% in the second quarter. Lynch & Associates IN now owns 91,451 shares of the company’s stock worth $13,366,000 after purchasing an additional 2,293 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $3.24 during trading on Wednesday, reaching $142.99. 2,331,664 shares of the company traded hands, compared to its average volume of 6,000,001. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a 50 day simple moving average of $150.75 and a 200-day simple moving average of $156.23. Johnson & Johnson has a 52-week low of $141.44 and a 52-week high of $168.85. The stock has a market capitalization of $344.27 billion, a PE ratio of 20.69, a P/E/G ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.66 EPS. Equities research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent research reports. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.